105 related articles for article (PubMed ID: 23354097)
1. Phosphorylation of IGFBP-1 at discrete sites elicits variable effects on IGF-I receptor autophosphorylation.
Abu Shehab M; Iosef C; Wildgruber R; Sardana G; Gupta MB
Endocrinology; 2013 Mar; 154(3):1130-43. PubMed ID: 23354097
[TBL] [Abstract][Full Text] [Related]
2. Total alanine-scanning mutagenesis of insulin-like growth factor I (IGF-I) identifies differential binding epitopes for IGFBP-1 and IGFBP-3.
Dubaquié Y; Lowman HB
Biochemistry; 1999 May; 38(20):6386-96. PubMed ID: 10350456
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor (IGF) binding protein-3 inhibits type 1 IGF receptor activation independently of its IGF binding affinity.
Ricort JM; Binoux M
Endocrinology; 2001 Jan; 142(1):108-13. PubMed ID: 11145572
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia alters phosphorylation status of insulin-like growth factor (IGF)-binding protein-1 and attenuates biological activities of IGF-I in HepG2 cell cultures.
Tsunawaki T; Sakai K; Momomura M; Wachi Y; Matsuzawa Y; Iwashita M
J Obstet Gynaecol Res; 2013 Sep; 39(9):1367-73. PubMed ID: 23815140
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.
Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB
Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of insulin-like growth factor (IGF)-binding protein-3 and its proteolytic fragments on ligand binding, cell surface association, and IGF-I receptor signaling.
Devi GR; Yang DH; Rosenfeld RG; Oh Y
Endocrinology; 2000 Nov; 141(11):4171-9. PubMed ID: 11089550
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of rat insulin-like growth factor binding protein-1 does not affect its biological properties.
Peterkofsky B; Gosiewska A; Wilson S; Kim YR
Arch Biochem Biophys; 1998 Sep; 357(1):101-10. PubMed ID: 9721188
[TBL] [Abstract][Full Text] [Related]
8. Human IGFBP-1 is phosphorylated on 3 serine residues: effects of site-directed mutagenesis of the major phosphoserine.
Jones JI; Busby WH; Wright G; Clemmons DR
Growth Regul; 1993 Mar; 3(1):37-40. PubMed ID: 7683525
[TBL] [Abstract][Full Text] [Related]
9. Binding protein-3-selective insulin-like growth factor I variants: engineering, biodistributions, and clearance.
Dubaquié Y; Mortensen DL; Intintoli A; Hogue DA; Nakamura G; Rancatore P; Lester P; Sadick MD; Filvaroff E; Fielder PJ; Lowman HB
Endocrinology; 2001 Jan; 142(1):165-73. PubMed ID: 11145579
[TBL] [Abstract][Full Text] [Related]
10. Structural changes in insulin-like growth factor (IGF) I mutant proteins affecting binding kinetic rates to IGF binding protein 1 and IGF-I receptor.
Jansson M; Uhlen M; Nilsson B
Biochemistry; 1997 Apr; 36(14):4108-17. PubMed ID: 9100004
[TBL] [Abstract][Full Text] [Related]
11. Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and -5 markedly reduce IGF-I binding and alter their biologic actions.
Imai Y; Moralez A; Andag U; Clarke JB; Busby WH; Clemmons DR
J Biol Chem; 2000 Jun; 275(24):18188-94. PubMed ID: 10766744
[TBL] [Abstract][Full Text] [Related]
12. Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors.
Reeve JG; Morgan J; Schwander J; Bleehen NM
Cancer Res; 1993 Oct; 53(19):4680-5. PubMed ID: 7691401
[TBL] [Abstract][Full Text] [Related]
13. Cumulative mutagenesis of the basic residues in the 201-218 region of insulin-like growth factor (IGF)-binding protein-5 results in progressive loss of both IGF-I binding and inhibition of IGF-I biological action.
Allan GJ; Tonner E; Szymanowska M; Shand JH; Kelly SM; Phillips K; Clegg RA; Gow IF; Beattie J; Flint DJ
Endocrinology; 2006 Jan; 147(1):338-49. PubMed ID: 16195401
[TBL] [Abstract][Full Text] [Related]
14. Site-specific IGFBP-1 hyper-phosphorylation in fetal growth restriction: clinical and functional relevance.
Abu Shehab M; Khosravi J; Han VK; Shilton BH; Gupta MB
J Proteome Res; 2010 Apr; 9(4):1873-81. PubMed ID: 20143870
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs.
Oh Y; Müller HL; Lee DY; Fielder PJ; Rosenfeld RG
Endocrinology; 1993 Mar; 132(3):1337-44. PubMed ID: 7679979
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor binding protein-5 (IGFBP-5) interacts with thrombospondin-1 to induce negative regulatory effects on IGF-I actions.
Moralez AM; Maile LA; Clarke J; Busby WH; Clemmons DR
J Cell Physiol; 2005 May; 203(2):328-34. PubMed ID: 15700281
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia and leucine deprivation induce human insulin-like growth factor binding protein-1 hyperphosphorylation and increase its biological activity.
Seferovic MD; Ali R; Kamei H; Liu S; Khosravi JM; Nazarian S; Han VK; Duan C; Gupta MB
Endocrinology; 2009 Jan; 150(1):220-31. PubMed ID: 18772238
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: studies of underlying mechanism.
Conover CA
Endocrinology; 1992 Jun; 130(6):3191-9. PubMed ID: 1375895
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells.
Yee D; Jackson JG; Kozelsky TW; Figueroa JA
Cell Growth Differ; 1994 Jan; 5(1):73-7. PubMed ID: 7510125
[TBL] [Abstract][Full Text] [Related]
20. Activity of human pregnancy insulin-like growth factor binding protein-3: determination by reconstituting recombinant complexes.
Yan X; Payet LD; Baxter RC; Firth SM
Endocrinology; 2009 Nov; 150(11):4968-76. PubMed ID: 19734278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
